Analysts expect that ADMA Biologics Inc (NASDAQ:ADMA) will post $2.96 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for ADMA Biologics’ earnings, with the lowest sales estimate coming in at $2.50 million and the highest estimate coming in at $3.30 million. ADMA Biologics posted sales of $4.04 million in the same quarter last year, which suggests a negative year-over-year growth rate of 26.7%. The business is scheduled to issue its next earnings report on Monday, May 13th.
On average, analysts expect that ADMA Biologics will report full-year sales of $34.22 million for the current financial year, with estimates ranging from $18.38 million to $94.20 million. For the next financial year, analysts forecast that the company will report sales of $82.70 million, with estimates ranging from $49.10 million to $197.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow ADMA Biologics.
Several equities research analysts recently commented on the company. WBB Securities upgraded ADMA Biologics to a “buy” rating in a research report on Thursday, April 4th. ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Maxim Group set a $12.00 target price on ADMA Biologics and gave the company a “buy” rating in a research report on Tuesday, April 2nd. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of ADMA Biologics in a research report on Thursday, February 21st. Finally, Oppenheimer set a $13.00 target price on ADMA Biologics and gave the company a “buy adma” rating in a research report on Thursday, December 20th. Nine analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $10.92.
A number of large investors have recently made changes to their positions in ADMA. Diag Capital Management LP bought a new position in ADMA Biologics in the fourth quarter worth approximately $435,000. Renaissance Technologies LLC boosted its holdings in ADMA Biologics by 544.9% in the third quarter. Renaissance Technologies LLC now owns 188,300 shares of the biotechnology company’s stock worth $1,169,000 after acquiring an additional 159,100 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in ADMA Biologics by 54.7% in the third quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock worth $1,422,000 after acquiring an additional 81,003 shares in the last quarter. Delek Group Ltd. boosted its holdings in ADMA Biologics by 102.5% in the fourth quarter. Delek Group Ltd. now owns 118,539 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 60,000 shares in the last quarter. Finally, Vanguard Group Inc boosted its holdings in ADMA Biologics by 5.2% in the third quarter. Vanguard Group Inc now owns 1,192,641 shares of the biotechnology company’s stock worth $7,406,000 after acquiring an additional 58,610 shares in the last quarter. Institutional investors and hedge funds own 53.30% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.